GlaxoSmithKline: The proportion of patients without progression reached 90% at 12 months, and the median progression-free survival period has not yet been achieved.

GlaxoSmithKline: The proportion of patients without progression reached 90% at 12 months, and the median progression-free survival period has not yet been achieved.